SciSparc Subsidiary Seeks FDA Orphan Drug Designation for Adult Tourette Syndrome Treatment

NeuroThera Labs, a subsidiary of SciSparc, is pursuing FDA orphan drug designation for a new medication targeting adult Tourette syndrome and has hired RK Strategies for government affairs.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

taiwan-newsFrench1d ago

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - Taiwan News

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies Taiwan News

Read full article →

SciSparc Subsidiary Seeks FDA Orphan Drug Designation for Adult Tourette Syndrome Treatment

Sources

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - Taiwan News

Related Stories

UNICEF Report Finds 20 Million Children Annually Face Online Sexual Exploitation

Genetically Modified Pig Kidney Keeps US Patient Alive for Record Nine Months

Pentagon Temporarily Rescinds Testosterone Screening Guidance for Troops

RFK Jr. Allegedly Requested Removal of Measles Deaths From CDC Tally